RiboMed Biotechnologies is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in personalized medicine. It is focused on the detection of epigenetic biomarkers (DNA methylation) associated with disease initiation, progression, and response to drug treatment. The company also offers testing of brain tumors (gliomas) for MGMT methylation and CIMP to predict drug response. In addition, it develops epigenetic based diagnostic tests for endometriosis and ovarian cancer.